Anti-angiogenesis in cancer therapy

Muehlbauer, Paula

doi:10.1016/s0749-2081(03)00046-9

Cited by 19 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiogenesis inhibitors show promise as anti-cancer agents as they can act in both pre-invasive and invasive stages of cancer (Lee et al, 2003;Muehlbauer, 2003). Favourably, endothelial cell recruitment and proliferation is a central phenomenon of all cancer types and these cells are inherently stable and exhibit low mutagenesis rate, thereby reducing chances of multi-drug resistance (Tosetti et al, 2002;Bisacchi et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis

Mathur

Gupta

Singh

et al. 2006

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis

Mathur

Gupta

Singh

et al. 2006

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…Preclinical trial: Orantinib (SU5416 SU6668)[94], pazopanib[100], sorafenib (Nexavar)[101,102], sunitinib (Sutent)[103,104] and telatinib (Erbitux, Cetuximab)[105] block tyrosine kinases and belong to the family of multitargeting TKIs. Suppressing the effects of VEGF by silencing RNA in GC cell lines led to decreased tumor angiogenesis and growth after these cells were implanted into nude mice.…”

Section: Direct Action On Ecsmentioning

confidence: 99%

Tumor progression-dependent angiogenesis in gastric cancer and its potential application

Hsieh

Tsai

2019

WJGO

View full text Add to dashboard Cite

Despite improvements in the early diagnosis, prognosis and therapeutic strategies for gastric cancer (GC), human GC remains one of the most frequently diagnosed malignant tumors in the world, and the survival rate of GC patients remains very poor. Thus, a suitable therapeutic strategy for GC is important for prolonging survival. Both tumor cells themselves and the tumor microenvironment play an important role in tumorigenesis, including angiogenesis, inflammation, immunosuppression and metastasis. Importantly, these cells contribute to gastric carcinogenesis by altering the angiogenic phenotype switch. The development, relapse and spreading of tumors depend on new vessels that provide the nutrition, growth factors and oxygen required for continuous tumor growth. Therefore, a state of tumor dormancy could be induced by blocking tumor-associated angiogenesis. Recently, several antiangiogenic agents have been identified, and their potential for the clinical management of GC has been tested. Here, we provide an up-to-date summary of angiogenesis and the angiogenic factors associated with tumor progression in GC. We also review antiangiogenic agents with a focus on the anti-vascular endothelial growth factor receptor (VEGFR)-mediated pathway for endothelial cell growth and their angiogenesis ability in GC. However, most antiangiogenic agents have reported no benefit to overall survival (OS) compared to chemotherapy alone in local or advanced GC. In phase III clinical trials, only ramucirumab (anti-VEGFR blocker) and apatinib (VEGFR-TKI blocker) have reported an improved median overall response rate and prolonged OS and progression-free survival outcomes as a 2nd-line agent combined with chemotherapy treatment in advanced GC. By providing insights into the molecular mechanisms of angiogenesis associated with tumor progression in GC, this review will hopefully aid the optimization of antiangiogenesis strategies for GC therapy in combination with chemotherapy and adjuvant treatment.

show abstract

“…Anti-angiogenic cytostatic agents were thought to have several advantages over the traditional cytotoxic chemotherapeutic agents 7,13,[15][16][17][18] . First, it was hypothesized that regardless of the extent of tumor heterogeneity, tumor angiogenesis is a non-neoplastic homogenous process; hence anti-angiogenic strategies would be efficacious against a variety of human solid cancers.…”

Section: Principles Of Anti-angiogenic Therapymentioning

confidence: 99%